Passage Bio Appoints Sandip Kapadia to Board of Directors
January 10, 2020 08:00 ET
|
Passage Bio
PHILADELPHIA, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system diseases, today...
Passage Bio to Present at Piper Jaffray 31st Annual Healthcare Conference
November 27, 2019 08:00 ET
|
Passage Bio
PHILADELPHIA, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system diseases, today...
Passage Bio to Present at Barclays Gene Editing & Gene Therapy Summit
November 06, 2019 08:00 ET
|
Passage Bio
PHILADELPHIA, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
Passage Bio Appoints Richard Morris as Chief Financial Officer
October 29, 2019 08:00 ET
|
Passage Bio
PHILADELPHIA, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
Passage Bio to Present at Upcoming Investor Conferences
September 25, 2019 08:00 ET
|
Passage Bio
PHILADELPHIA, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
Passage Bio Grows Management Team with Chief Medical Officer and General Counsel Appointments
September 23, 2019 08:00 ET
|
Passage Bio
PHILADELPHIA, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
Passage Bio Announces New Gene Therapy Development Program for Patients with Charcot-Marie-Tooth Neuropathy Type 2A
September 09, 2019 07:00 ET
|
Passage Bio
PHILADELPHIA, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system (CNS)...
Passage Bio Closes $110 Million Series B Financing
September 04, 2019 08:00 ET
|
Passage Bio
PHILADELPHIA, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system (CNS)...
Passage Bio to Present at Morgan Stanley 17th Annual Global Healthcare Conference
September 03, 2019 08:00 ET
|
Passage Bio
PHILADELPHIA, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
Passage Bio Announces Launch of Natural History Study to Evaluate Patients with GM1 Gangliosidosis
August 13, 2019 08:00 ET
|
Passage Bio
PHILADELPHIA, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...